Guangzhou Xingqun Pharmaceutical Ltd. is in the process of applying for a patent to market the first Traditional Chinese Medicine bird flu treatment, the company announced. If approved, Xia Sang Ju granules will become China's first TCM to prevent and treat bird flu, according to the company.

The granules were originally developed to prevent and treat colds and flu, treat sunstroke and to strengthen liver function. However, further research conducted by the company and the Hong Kong University of Science & Technology resulted in the discovery o anti-bird flu effects of Xia Sang Ju granules.

The granules can kill H3N2 and H5N1 viruses, and strains of influenza B, which enables them to prevent and control influenza A and B and bird flu, according to the company.

Xia Sang Ju granules contain extracts of prunella vulgaris, mulberry leaves, and chrysanthemum indicum. The sales of the granules are estimated to reach RMB 300 million ($37.5 million) this year, Sun said.

The company's prunella vulgaris planting bases are the only in China that meet good agricultural practice standards. Dominating with 80 percent market share in China, Xia Sang Ju granules are also marketed to Southeast Asian countries including Singapore and Malaysia.

A subsidiary of Guangzhou Pharmaceutical Group, Guangzhou Xingqun Pharma produces granules, soft and hard capsules, syrup, and oral solutions. Flagship products include Xia Sang Ju granules, and pediatric paracetamol artificial cow-bezoar and chlorphenamine maleate granules.

Source:佚名